On June 4, 2024, HOOKIPA Pharma Inc. announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab for treating patients with HPV16+ recurrent/metastatic head and neck cancer. The data, presented at the American Society for Clinical Oncology 2024 Annual Meeting, included 46 first line patients and demonstrated a favorable safety profile and promising clinical activity. Among 35 evaluable patients, there were 4 complete responses, 9 partial responses, and 11 stable disease cases. Notably, in a subset of patients with high PD-L1 levels, the objective response rate was 53%, with a disease control rate of 82%. The preliminary progression-free survival for this subgroup was 16.3 months, and the overall survival rate was 88% at 9 months, with median overall survival not yet reached. The median follow-up time...Show More

On June 4, 2024, HOOKIPA Pharma Inc. announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab for treating patients with HPV16+ recurrent/metastatic head and neck cancer. The data, presented at the American Society for Clinical Oncology 2024 Annual Meeting, included 46 first line patients and demonstrated a favorable safety profile and promising clinical activity. Among 35 evaluable patients, there were 4 complete responses, 9 partial responses, and 11 stable disease cases. Notably, in a subset of patients with high PD-L1 levels, the objective response rate was 53%, with a disease control rate of 82%. The preliminary progression-free survival for this subgroup was 16.3 months, and the overall survival rate was 88% at 9 months, with median overall survival not yet reached. The median follow-up time was 8.4 months. HOOKIPA Pharma also plans to initiate a pivotal Phase 2/3 trial in the fourth quarter of 2024. The company's CEO, Joern Aldag, highlighted the potential of HB-200 plus pembrolizumab as a targeted therapeutic option and emphasized the alignment with the FDA on a clinical development strategy that could lead to accelerated approval.